BioCentury
ARTICLE | Clinical News

BPX-01: Completed Phase IIa enrollment

May 2, 2016 7:00 AM UTC

BioPharmX completed enrollment of 30 patients in a double-blind, placebo-controlled, U.S. Phase IIa trial evaluating once-daily BPX-01 1% topical gel for 4 weeks. ...